Abstract
Purpose of Review: The goal of this review is to provide a practical and comprehensive update on changes in the classification of chronic myelomonocytic leukemia (CMML) and a summary of the most recent developments in our understanding of its genomic landscape, prognostic models, and therapeutic approaches. Recent Findings: The 2017 revision of the World Health Organization (WHO) classification includes substantial changes to the subclassification CMML. The clinical utility of the newly revised subclassification scheme is discussed. In addition, we provide an overview of the genetic changes involved in the pathogenesis of CMML and discuss the clinical utility of the more recently developed molecularly integrated prognostic models and their management and therapeutic implications. Finally, we provide an overview of the currently available treatment options for patients with CMML. Summary: The classification of CMML as well as our understanding of its genomic landscape and optimal treatment approaches has advanced significantly over the past decade but remains in flux.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 446-454 |
| Number of pages | 9 |
| Journal | Current hematologic malignancy reports |
| Volume | 13 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 1 2018 |
Keywords
- ASXL1
- CMML
- Chronic myelomonocytic leukemia
- MDS
- MPN
- Monocytosis
- SRSF2
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research